Apex Labs Granted Approval for 294 Patient Take Home Psilocybin Clinical Trial Post published:February 1, 2023 Post category:Press Release
Kabir Nath: Our Mission, Progress and Future Perspectives Post published:January 31, 2023 Post category:2022 Year in Review
Israeli Biotech Clearmind Medicine Announces Positive Pre-Clinical Results Treating Major Depression With a Novel Ketamine-Based Compound Post published:January 31, 2023 Post category:Press Release
Silo Pharma Announces Stock Repurchase Program Post published:January 31, 2023 Post category:Press Release
Late-Stage Psychedelic Trials: A brief review of the two most mature psychedelic drug development programs Post published:January 30, 2023 Post category:2022 Year in Review
Bright Minds Biosciences Announces Receipt of Nasdaq Notification Letter Regarding Minimum Bid Price Deficiency Post published:January 28, 2023 Post category:Press Release
Doing Things Differently: Beyond Business as Usual in the Psychedelics Space Post published:January 27, 2023 Post category:2022 Year in Review
Adelaide Wilcox King: The Psychedelic Industry as a Catalyst for Reimagining Capitalism and the Purpose-Driven Firm Post published:January 27, 2023 Post category:2022 Year in Review
Julia Mande: Consider the Conditions: Growing a Psychedelic Ecosystem Post published:January 27, 2023 Post category:2022 Year in Review
BetterLife Announces Engagement of Bloom Burton Securities Inc. and Provides Summary of 2022 Accomplishments Post published:January 27, 2023 Post category:Press Release